Technology
Health
Pharmaceutical

Adamis Pharmaceuticals

$1.90
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.06 (3.26%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell ADMP and other stocks, options, ETFs, and crypto commission-free!

About

Adamis Pharmaceuticals Corporation Common Stock, also called Adamis Pharmaceuticals, is a biopharmaceutical company, which engages in the discovery, development and sales of pharmaceutical, specialty biopharmaceutical and other drug products. It offers Symjepi product for allergy, respiratory, opioid overdose, and erectile dysfunction (ED), markets. Read More The company was founded in June 2006 and is headquartered in San Diego, CA.

Employees
152
Headquarters
San Diego, California
Founded
2006
Market Cap
90.14M
Price-Earnings Ratio
β€”
Dividend Yield
0.00
Average Volume
611.08K
High Today
$1.92
Low Today
$1.83
Open Price
$1.84
Volume
83.84K
52 Week High
$5.10
52 Week Low
$1.83

Collections

Technology
Health
Pharmaceutical
Biopharmaceutical
US
North America

News

Seeking AlphaMay 10

Adamis Pharmaceuticals' CEO Dennis Carlo on Q1 2019 Results - Earnings Call Transcript

Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) Q1 2019 Results Earnings Conference Call May 9, 2019 5:00 PM ET Company Participants Dennis Carlo – President and Chief Executive Officer Rob Hopkins – Chief Financial Officer Ronald Moss – Chief Medical Officer Dave Marguglio – Chief Business Officer Conference Call Participants Elliot Wilbur – Raymond James Jason McCarthy – Maxim Group Jason Kolbert – Dawson James Operator Good day and welcome to the Adamis Pharmaceuticals Corp First Quarter 2019...

199
Yahoo FinanceMay 7

Adamis Pharmaceuticals Schedules First Quarter 2019 Earnings Conference Call and Business Update

SAN DIEGO, May 07, 2019 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) (β€œAdamis”), a specialty biopharmaceutical company primarily focused on developing and commercializing products in various therapeutic areas including respiratory disease and allergy, announced today that it will host an investor conference call on Thursday, May 9, 2019 at 2:00 pm Pacific Time to discuss its financial and operating results for the first quarter of 2019 as well as provide an update on business developments and activities.

354
Yahoo FinanceMay 2

Adamis Pharmaceuticals (ADMP) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

Adamis Pharmaceuticals (ADMP) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended March 2019. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price.

269

Earnings

-$0.29
-$0.25
-$0.20
-$0.16
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
-$0.16 per share
Actual
-$0.19 per share

Popular Stocks

All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.